NCI CTEP-Approved Trials for the Month of February

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Phase II

GOG-0283: A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND# 120636) in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression. Gynecologic Oncology Group; Hyman, David Michael. (212) 639-2000

Phase III

E1912: A Randomized Phase III Study of Ibrutinib (PCI-32765) Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL). Eastern Cooperative Oncology Group; Shanafelt, Tait D. 507-284-2358

Other Phases

AAML13B7-Q: Prognostic Significance of MMRN1 in Pediatric Acute Myeloid Leukemia (AML). Children’s Oncology Group; Walter, Roland Bruno. (206) 667-3599

AAML13B8-Q: Global Proteomic and Phosphoproteomic Profiling of Normal B Cells Isolated from COG AAML1031 Study Patients in AML Remission. Children’s Oncology Group; Pandey, Akhilesh. (410) 502-6662

ANBL13B9-Q: 3D Nuclear Telomere Organization in Neuroblastoma. Children’s Oncology Group; Mai, Sabine. (204) 787-2135

ANBL13B10-Q: The Role of FGFR4 in Neuroblastoma Pathogenesis. Children’s Oncology Group; Zage, Peter Eric. (832) 824-4615

AREN13B2-Q: Characterization of the Chromosome 11p15 Imprinting Regulation by Epigenetic and Transcriptomic Analyses in Wilms Tumor Patients. Children’s Oncology Group; Michels, Karin B. (617) 732-4895

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

36 months to live, 29 months to wait. Why is Congress withholding lifesaving benefits from breast cancer patients?

In this episode of The Cancer Letter Podcast, Fran Visco, president of the National Breast Cancer Coalition, and Jacquelyn Cobb, managing editor of The Cancer Letter, discuss the Metastatic Breast Cancer Act, bipartisan legislation that would eliminate the waiting periods for Social Security Disability Insurance and Medicare for eligible people with metastatic breast cancer.

September 23, 2026

NCI

Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI
“To my knowledge, 100% of grants that clear my desk get funded”

As of the end of August, NCI has selected 1,891 competing awards for funding this fiscal year, all of which will be funded by the year’s end, NCI Director Anthony G. Letai said to the National Cancer Advisory Board.

September 18, 2026

Vol.52 No.34

By Claire Marie Porter

Health Equity

As Medicaid work requirements loom, CMS guidance offers automatic exemptions for some cancer patients
Caveat: The guidance is optional. Will states opt in?

The Centers for Medicare & Medicaid Services has published a guidance that spells out a process for states to use to exempt Medicaid recipients from the controversial work requirements established last year under President Trump’s “One Big Beautiful Bill Act.”

Scientific progress can’t help people if they can’t access care
This is a policy problem. And it is one we can change.

Scientific advances have produced therapies that allow some people with metastatic breast cancer to live longer and better. We want that progress to continue, and we will continue to fight for the right research necessary to achieve it.

September 18, 2026

Vol.52 No.34

By Frances M. Visco and Michelle Tregear

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.

Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel

Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

September 18, 2026

Vol.52 No.34

By Paul Goldberg

NCI CTEP-Approved Trials for the Month of February

YOU MAY BE INTERESTED IN

36 months to live, 29 months to wait. Why is Congress withholding lifesaving benefits from breast cancer patients?

Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI
“To my knowledge, 100% of grants that clear my desk get funded”

As Medicaid work requirements loom, CMS guidance offers automatic exemptions for some cancer patients
Caveat: The guidance is optional. Will states opt in?

Scientific progress can’t help people if they can’t access care
This is a policy problem. And it is one we can change.

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel

Renew today!

Subscriber content

Never miss an issue!

Login

NCI CTEP-Approved Trials for the Month of February

YOU MAY BE INTERESTED IN

36 months to live, 29 months to wait. Why is Congress withholding lifesaving benefits from breast cancer patients?

Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI“To my knowledge, 100% of grants that clear my desk get funded”

As Medicaid work requirements loom, CMS guidance offers automatic exemptions for some cancer patientsCaveat: The guidance is optional. Will states opt in?

Scientific progress can’t help people if they can’t access careThis is a policy problem. And it is one we can change.

The end of “more money, more people, more trials”Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Harold Freeman, a surgeon who championed health equity, dies at 93Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel

Never miss an issue!

Login

Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI
“To my knowledge, 100% of grants that clear my desk get funded”

As Medicaid work requirements loom, CMS guidance offers automatic exemptions for some cancer patients
Caveat: The guidance is optional. Will states opt in?

Scientific progress can’t help people if they can’t access care
This is a policy problem. And it is one we can change.

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel